Consenso del Grupo Latinoamericano de estudio de Mieloma Múltiple (MM) GELAMM para el manejo del MM en estado de Pandemia SARS CoV-2 / COVID 19

IF 0.2 Q4 ONCOLOGY

Revista Colombiana de Cancerologia Pub Date : 2020-05-22 DOI:10.35509/01239015.656

Humberto Martinez-Codero, L. Martínez, Juan Alejandro Ospina Idárraga, Guillermo J Ruiz Argüelles, Virginia Abello Polo, Camila Peña Ojeda, Macarena Roa, Carlos Fernández de Larrea, Rosa Olday Ríos Jiménez, D. Fantl, Natalia Schutz, E. Riva, Fiorella Villano, Henry Idrobo, V. Bove, Manuel Antonio Granja Morá, M. Zamora

{"title":"Consenso del Grupo Latinoamericano de estudio de Mieloma Múltiple (MM) GELAMM para el manejo del MM en estado de Pandemia SARS CoV-2 / COVID 19","authors":"Humberto Martinez-Codero, L. Martínez, Juan Alejandro Ospina Idárraga, Guillermo J Ruiz Argüelles, Virginia Abello Polo, Camila Peña Ojeda, Macarena Roa, Carlos Fernández de Larrea, Rosa Olday Ríos Jiménez, D. Fantl, Natalia Schutz, E. Riva, Fiorella Villano, Henry Idrobo, V. Bove, Manuel Antonio Granja Morá, M. Zamora","doi":"10.35509/01239015.656","DOIUrl":null,"url":null,"abstract":"COVID-19 disease was detected at the end of 2019 in Wuhan, China. Due it´s quickly spread was declared a health emergency initially and after identifying cases outside China with indigenous transmission, characterized by considerably high mortality in countries such as Italy and Spain, it was declared a pandemic by the World Health Organization. It has been shown that older patients with a history of chronic diseases including cancer develop severe disease, presenting a higher risk of mortality from SARS-CoV2 / COVID-19. This is especially important in the handle of patients with Multiple Myeloma (MM), generating new challenges, improvement and learning opportunities for Medical group, that contribute to the risk-benefit analysis of immunosuppressive treatment for this type of pathology. \nThe consensus aims to provide guidance for the management of patients with MM in this time where the health professional requires information to carry out efficient therapies in patient care.","PeriodicalId":42496,"journal":{"name":"Revista Colombiana de Cancerologia","volume":null,"pages":null},"PeriodicalIF":0.2000,"publicationDate":"2020-05-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"2","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Revista Colombiana de Cancerologia","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.35509/01239015.656","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 2

Abstract

COVID-19 disease was detected at the end of 2019 in Wuhan, China. Due it´s quickly spread was declared a health emergency initially and after identifying cases outside China with indigenous transmission, characterized by considerably high mortality in countries such as Italy and Spain, it was declared a pandemic by the World Health Organization. It has been shown that older patients with a history of chronic diseases including cancer develop severe disease, presenting a higher risk of mortality from SARS-CoV2 / COVID-19. This is especially important in the handle of patients with Multiple Myeloma (MM), generating new challenges, improvement and learning opportunities for Medical group, that contribute to the risk-benefit analysis of immunosuppressive treatment for this type of pathology. The consensus aims to provide guidance for the management of patients with MM in this time where the health professional requires information to carry out efficient therapies in patient care.

查看原文本刊更多论文

拉丁美洲多发性骨髓瘤(MM)研究小组GELAMM对SARS CoV-2 / COVID - 19大流行状态下MM管理的共识

新冠肺炎于2019年底在中国武汉被检测到。由于它的快速传播最初被宣布为卫生紧急状态，在发现中国以外的本土传播病例后，世界卫生组织宣布它为流行病，意大利和西班牙等国的死亡率相当高。研究表明，有包括癌症在内的慢性病病史的老年患者会发展成严重疾病，导致SARS-CoV2/新冠肺炎死亡的风险更高。这在多发性骨髓瘤（MM）患者的治疗中尤为重要，为医疗团队带来了新的挑战、改进和学习机会，有助于对这类病理的免疫抑制治疗进行风险效益分析。该共识旨在为MM患者的管理提供指导，在这个时候，卫生专业人员需要信息来在患者护理中进行有效的治疗。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Revista Colombiana de Cancerologia ONCOLOGY-

自引率

50.00%

发文量

期刊介绍： The Revista Colombiana de Cancerología is an official publication of the Instituto Nacional de Colombia (INC). The Revista is published quarterly with the aim of broadening and disseminating knowledge in the field of oncology. The Revista publishes articles on: molecular carcinogenic mechanisms and treatment responses; cancer epidemiology; clinical features and treatment of neoplastic disease and public health campaigns to control cancer. Manuscripts which contain original material shall be accepted for possible publication. Neither the article nor any part of its contents (including statistical or graphic content) may have been published or submitted for publication in any media other than the Revista Colombiana de Cancerología. No acceptance shall be made of preliminary reports (abstracts or posters) presented at scientific meetings, neither of press releases on programmed meetings. All manuscript copies shall be placed at the disposition of the Journal Editorial Board. Under exceptional circumstances, secondary publications in Spanish or other languages may be submitted, provided they comply with certain conditions which justify said submission.